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Computedtomography(CT)isaclinicaltoolwidelyusedtoassessandfollowupasthmaandchonicobstructivepulmonarydisease
(COPD) in humans. Strong eﬀorts have been made the last decade to improve this technique as a quantitative research tool. Using
semiautomatic softwares, quantiﬁcation of airway wall thickness, lumen area, and bronchial wall density are available from large to
intermediate conductive airways. Skeletonization of the bronchial tree can be built to assess its three-dimensional geometry. Lung
parenchyma density can be analysed as a surrogate of small airway disease and emphysema. Since resident cells involve airway wall
and lung parenchyma abnormalities, CT provides an accurate and reliable research tool to assess their role in vivo. This litterature
review highlights the most recent advances made to assess asthma and COPD with CT, and also their drawbacks and the place of
CT in clarifying the complex physiopathology of both diseases.
1.Introduction
Asthma and chronic obstructive pulmonary disease (COPD)
are the most common airway diseases worldwide and aﬀect
millions of people, with an increasing incidence. Asthma
is characterized by a reversible airway obstruction and a
bronchial hyperreactivity in response to a stimulus. Con-
versely COPD is deﬁned as a chronic airway obstruction
which is progressive and poorly reversible [1, 2]. Both dis-
eases are associated with environmental factors such as aller-
gens, viruses, bacteria, or toxics leading to an inﬂammatory
response in patients genetically susceptible. Airway inﬂam-
mation triggers oedema and bronchial wall inﬁltration by
resident cells [3] (neutrophils, macrophages, mast cells [4],
and eosinophils in asthma). Chronic inﬂammation leads to
airway remodelling, and despite similarities, many clinical
and pathological features show that the two diseases are
distinct [5, 6]. The epithelium appears to be more fragile in
asthma, and the epithelial membrane thickness and the
bronchial smooth muscle are thicker than in COPD. Emphy-
sema does not occur in asthmatic nonsmoker. In COPD, the
epithelium displays mucous metaplasia, and inﬂammation is
associated with loss of alveolar attachments, surrounded by
peribronchial ﬁbrosis [7]. Destruction of alveolar wall leads
to emphysema which is a structural alteration seen in severe
COPD. Beyond the immune system, asthma and COPD
involveairwayandlungparenchymamorphologicalchanges,
andcomputedtomography(CT)appearstobe anoninvasive
tool to investigate them in vivo [8, 9]. Submillimetric ac-
quisition can be obtained with an isotropic voxel over the
wholelungvolume,andfullyautomaticquantiﬁcationmeas-
urements are achievable using commercially available soft-
wares. It provides an accurate research tool, suitable to help
understand the complex physiopathology underlying the
two diseases, which is still not well known [10]. Clinical,
functional, and histological correlations have been reported.
Thisarticleisfocusedonthemostrecentdevelopmentsmade
the last decade to improve this technique, their ﬁndings and
also their limits, and their perspectives.
2. QuantitativeMeasurementof Airwaysand
LungParenchymaUsing CT
2.1. Quantiﬁcation of Airway Wall. The rationale of airway
wall quantiﬁcation using CT is the presence of an increased2 Journal of Allergy
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Figure 1: (a) Thin-section CT image perpendicular to the third generation of the right segmental apical bronchus, from a random patient.
Red line indicates the external wall contour, and green line the internal layer. (b) Theoric single intensity curve (blue line) representing voxel
attenuation variation along the blue arrow seen in right image. The bronchial wall thickness calculated with the FWHM principle is given
by the diﬀerence between the two extreme values at which the mural portion attenuation is equal to half to its maximum (green and red
dashed lines). According to Washko et al., the local Peak Wall Attenuation is given by the maximum attenuation value within the region
of interest. Mean bronchial wall thickness and mean Peak Wall Attenuation shall be calculated using a circumferential integration of 128
one-dimensional rays, radiating outward the centroid of the bronchial lumen.
airway wall thickness in asthmatic and COPD patients com-
paredwithcontrolsubjects[11–15].Theairwayintraluminal
area (LA) and the total bronchial layer area (WT) are meas-
ured, in millimetres square. The wall area (WA) corresponds
to the diﬀerence WA = WT − LA. WA% represents WA
normalised on WT, that is, WA% = (WA/WT) × 100. WA
and LA are not independent from body height, so they need
to be normalised on body surface area (BSA), to reduce
interindividual variation.
A manual method of segmentation has been described
ﬁrst [11]. It consists in tracing a manual region of interest
around the internal and external bronchial wall, with a con-
tinuous extrapolation. This method is time consuming,
exposed to intra- and interobserver variability and parallax
error when the reconstructed plane is not strictly perpendic-
ulartothebronchusmainaxis.Justafewnumbersofbronchi
divisions are reasonably available using this method, and the
trunk of the right apical bronchus is the main target, owing
to its geometry, nearly perpendicular to the axial plane.
Semiautomatic computational methods have been later
developed to allow automated segmentation of the wall
contours [12–14] and the bronchial tree [15, 16]. Brieﬂy,
active energy-driven contours are a region-based active con-
tour model to extract the local image information. The full-
width-at-half-maximum (FWHM) principle is given by the
diﬀerence between the two extreme values at which the wall
attenuation is equal to half to its maximum (Figure 1). The
Laplacian-of-Gaussianalgorithmis afunctionthat combines
aL a p l a c eo p e r a t o rt od e t e c te d g e sa sw e l la sn o i s e ,a n da
convolution with a Gaussian kernel to smooth the image
ﬁrst. These algorithms have been used to segment airways
wall contours, but none of them have demonstrated any
superiority from each other. However, Brillet et al. have
proven that they are not interchangeable in longitudinal
studies [14].
Fetita et al. [15] and Montaudon et al. [16]h a v er e p o rt e d
three-dimensional softwares to segment semiautomatically
the bronchial tree (Figure 2). Perpendicular planes across the
targeted bronchi can be acquired, and WA indices are auto-
matically extracted. These softwares allow a fast and accurate
postprocessing quantiﬁcation, and this is relevant knowing
the heterogeneity of alterations in asthma. However, the
bronchial human tree displays a mean of 24 divisions in-
cluding the trachea, and only 10 divisions are reasonably
achievable using either manual or semiautomatic methods.
Small conductive airways less than 1-2mm diameter are not
clearly visible on CT scans.
Another quantitative parameter has recently been as-
sessed in both asthma and COPD: the bronchial wall at-
tenuation [17–19]. Lederlin et al. [17], in a murine model
of asthma, measured the peribronchial attenuation (PBA)
using micro-CT with a spatial resolution of 46 microns.
The manual method described in their study consisted in a
manual segmentation of the peribronchial area, arbitrarily
equal to the radius of the target bronchi lumen. In COPD,
Washko et al. [18] and Yamashiro et al. [19] studied the peak
wall attenuation (PWA) value, extracted from bronchial wall
single-intensitycurvesbasedonFWHMprinciple(Figure 1).
The mean PWA was calculated by taking the mean peak
attenuationalong128one-dimensionalmuralrays,radiating
outward from the centroid of the airway lumen, using a
circumferential measure.Journal of Allergy 3
Figure 2: Bronchial tree volume automatically segmented using
homemade dedicated software, extracted from a whole set of lung
CTimages. Theskeleton of thebronchial treeis computed to obtain
a simpliﬁed three-dimensional geometry of the bronchial tree.
2.2. Quantiﬁcation of Lung Parenchyma. Small conductive
and distal airways are beyond the spatial resolution of CT.
Intralobularstructuresarenotclearlyvisible,suchasalveolar
membranes, capillaries, or interstitial tissue. However, lung
parenchyma density is a consequence of the X-ray attenu-
ation by these lung structures, and any change in either of
them may modify it. Therefore, lung attenuation provides
an indirect tool to assess structural changes in distal airways,
though it is nonspeciﬁc [20].
Lung alterations can be seen on CT images such as
centrilobular micronodules, ground-glass opacities, mosaic
pattern, air trapping, and emphysema and have been de-
scribed in both pathologies [21, 22]. Quantiﬁcation of these
abnormalities has been studied through visual grading, but
this method is potentially exposed to variability [23].
In asthma, Mikos et al. [24] measured air trapping on
CT scans thanks to a manual method, at a window level of
−600HUandawindowwidthof1600HU.Focalairtrapping
was assessed on end-expiratory scans, superimposing a 10 ×
10mm grid. The number of squares containing low lung
attenuation was counted manually in every lung section.
Diﬀuse air trapping was assessed as the ratio between
mean lung density in expiration and inspiration (E/I ratio).
Landmarks to match inspiratory and expiratory scans were
placed at ﬁve levels, on superior margin of the aortic arch,
tracheal carina, 1cm below the carina, inferior pulmonary
veins, and 2cm above the diaphragm.
Two semiautomatic methods have been further devel-
oped [25, 26]. The rationale is the lower lung attenuation
measured in emphysema and air trapping areas compared
with normal areas. (a) The density mask technique [25]i s
based on a predeﬁned voxel as a threshold to diﬀerentiate
between areas of normal attenuation values, and areas of
low attenuation (LAA). The density mask technique is
deﬁned as the percentage LAA% of total lung volume that
contains voxels of lower attenuation values, usually lower
than −960UH in COPD to assess emphysema (Figure 3).
(b) The percentile method [26] is based on predeﬁned
percentages (1%, 5%, 10%, and 15%) at which voxels have
lower attenuation values (Figure 4).
Some drawbacks of these methods have been reported.
Since lung attenuation values are not the same between
diﬀerent levels of radiation doses, CT manufacturers [27],
or postprocessing softwares [28], Bakker et al. suggested that
a calibration of air and blood should be performed before
multicenter or longitudinal clinical trials and showed that
normalisation of CT quantitative measurements by mean air
attenuation value can reduce the variability.
Age and lung volume involve variation of the voxel
attenuation values, but not sex gender [29]. Densities are not
the same on inspiration or expiration CT scans [30, 31]. The
15th percentile method has been reported to be more inde-
pendent from lung volume changes than the density mask.
Stoel et al. recommend adjusting the 15th percentile to the
lung volume to reduce variability in followup studies [32].
Attenuation values are modiﬁed when CT is performed
with or without contrast injection. Heussel et al. showed
higher density in the lung parenchyma after contrast
application. Therefore, the amount of emphysema may be
underestimated, and they concluded that nonenhanced CT
scans should be the reference [33].
3.QuantitativeCTinAsthma
3.1. Large and Intermediate Airway Assessment in Asthma.
Asthma involves both proximal and distal airways [1, 2].
Several studies have shown that airway wall thickness (WA)
indices are increased in asthmatic patients compared with
healthy volunteers [34–37]. According to histological data
coming from autopsy studies of fatal cases, this may result
from inﬂammatory changes such as oedema and inﬁltration
of inﬂammatory cells, and structural changes such as an
increased basal membranous thickness, smooth muscle cell
layer and peribronchial ﬁbrosis. From bronchial biopsies,
Aysola et al. found that WA/LA ratio reﬂect increase in
epithelial, and lamina reticularis thickness [38]. Montaudon
et al. found that the slope and the maximal local slope
of the WA/LA ratio both correlated with the subepithelial
membrane thickness [39]. They showed that the bronchial
geometric parameters correlated with smooth muscle area
and with inﬁltration of the smooth muscle by mast cells.
ThelinkbetweenairwaythicknessmeasuredonCTscans
and bronchial reactivity (AHR) is controversial. The most
commonacceptedtheoryisthatpartoftheairwaywallthick-
ness is due to an increased smooth muscle cell layer, which
is leading to AHR. Boulet et al. found a positive correlation
between airway wall thickness and bronchial hyperreactivity,
measured as a fall of 20% of forced expiratory volume in
one second (FEV1) after a provocative concentration of
metacholine [34]. However, Niimi et al. found that airway
sensitivity was related to sputum eosinophil count but not
to airway thickness. They also showed a negative correlation
between airway thickness and bronchial reactivity, unrelated4 Journal of Allergy
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Figure 3: (a) Segmented thin-section CT image of basal left lung area in which lung contours and mediastinum were removed. (b) Same
image using the density mask technique.
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Figure 4: Theoric models of voxel attenuation frequencies in a
normal subject (green curve) and emphysematous patient (red
curve). The density mask technique is deﬁned as the percentage
of total lung volume that contains voxels lower than a predeﬁned
voxelindex,usually −950HUtoassessemphysema(purplearrows).
The percentile method is based on predeﬁned percentages at which
voxels have lower attenuation values. Blue arrows indicate the
crossing points of green and red curves with the 15th percentile.
to eosinophil count. They concluded that airway walls are
stiﬀ when thickened, indicating that remodelled asthmatic
airways are less distensible and may explain chronic airway
obstruction [35]. In other studies, the same authors showed
that WA indices are increased in severe as in mild-to-
moderate patients with asthma compared with control
subjects. In addition, they showed that WA indices correlate
with the duration of disease, the severity, and the degree of
airﬂow obstruction [36].
Data around intraluminal area (LA) are controversial
too. Niimi et al. [36] and Aysola et al. [38] did not ﬁnd
any signiﬁcant diﬀerence between asthmatic patients and
controls. Lynch et al. reported that 77% of asthmatic patients
had an internal bronchial diameter to pulmonary artery
ratio >1.0, indicating bronchial dilatation [37]. Conversely,
Montaudon et al. [39] and Beigelman-Aubry et al. [40]
reportedabronchialcross-sectionalareasigniﬁcantlysmaller
in asthmatic than in healthy volunteers. These diﬀerent fea-
tures may be explained by heterogeneity of bronchial diame-
ters in asthma. For instance, Niimi et al. measured the right
apical segmental bronchus, whereas Aysola et al. quantiﬁed
the ﬁrst to the third generation, and Montaudon et al. from
the fourth to the tenth.
Peribronchial density has been recently assessed by
Lederlin et al. in a murine model of asthma [17]. They did
not quantiﬁedWA orLA,butmicro-CT peribronchial densi-
ty (PBA), and showed that the attenuation around the bron-
chial tree in asthmatic mice was increased compared with
controls. This increase correlated with both inﬂammation
and remodelling features.
CT bronchial dimensions have been studied to assess
medication eﬀects. Kurashima et al. used CT to evaluate the
eﬃcacy of inhaled corticosteroid and found a decrease in
airway wall thickness among asthmatic patients with dura-
tion of symptoms less than 3 years, a minor response among
3 to 5 years and no change in wall thickness in patients
with more than 5 years duration of disease [41]. However,
Brillet et al. did not found any change of both WA and
LA after a combination of salmeterol/ﬂucitasone daily for
12 weeks, though patients displayed clinical and functional
improvement, assessed by a decrease in FEV1 and expiratory
reserve volume (ERV) [42].
3.2. Lung Parenchyma Assessment in Asthma. Asthma is a
predominant airway diseases and does not involve lungJournal of Allergy 5
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Figure 5: Ventral views of lung attenuation volume samples, computed using the density mask technique to extract voxels below −850HU.
Green areas are representative of voxels between −850 and −900HU, and blue areas between −900 and −950HU. Images (a) and (b) were
acquired with spirometrically gated CT scans in a non-severe asthmatic subject, in inspiration (a) and in expiration (b). Same images were
acquired at same levels of inspiration (c) and expiration (d) from a severe asthmatic subject.
parenchymadestructionduringstablestages[1,2].However,
CT lung parenchyma changes have been reported.
Using a visual grading, Laurent et al. observed that
the mosaic perfusion pattern was signiﬁcantly increased at
full inspiration in 22 patients with stable moderate asthma
(23%), compared with 12 healthy nonsmoker [21]. This
result was addressed to either hypoxic vasoconstriction or
small airway obstruction. They also found that air trapping
was increased in asthmatic and healthy smokers, but not in
controls. In asthmatic patients, air trapping scores correlated
with FEV1 and FEF25–75%, and this was ascribed to small
airway obstruction.
Mikos et al. using a manual method, showed that focal
and diﬀuse air trapping (E/I ratio) correlated with airway
wall thickness (WA%) [24]. Focal air trapping was signiﬁ-
cantly increased in a subgroup of 10 asthmatics patients with
normal FEV1% predicted and FEV1/FVC%.
In a multivariate analysis of risk factors, Busacker et al.
studied 60 patients with severe asthma, 34 nonsevere asthma
and 26 controls. Using a semiautomatic method of CT
quantiﬁcation based on the density mask technique, he
deﬁned air trapping as areas of attenuation lower than
−850HU on CT scans acquired in expiration. Air trapping
was considered signiﬁcant whether more than 9.66% of the
whole lung volume was involved (Figure 5). They analysed
that patients with the air trapping phenotype are more likely
to have a history of asthma-related hospitalizations and
mechanical ventilation. Several risk factors of this phenotype
where noted such as a history of pneumonia, neutrophilic
inﬂammation, and atopy [43].
Mitsunobu et al. evaluated the heterogeneity of asthma
disease using LAA% and a fractal analysis, to extract a D
coeﬃcient as a surrogate of small airway geometry complex-
ity [44]. They found that LAA% and D correlated in a subset
of asthmatic smokers, but not in nonsmokers. LAA% was
diﬀerent in mild and moderate asthma, but D was not.
They concluded that D was a biomarker of emphysematous
changes, which can help to characterize areas of low attenua-
tion.
Lung density has been used to evaluate CT changes after
therapy. Mitsunobu et al. demonstrated that mean lung
density (MLD) and relative lung areas of attenuation under6 Journal of Allergy
−950HU were improved after systemic glucocorticoid ther-
apy [45]. MLD and LAA% under −950HU both correlated
with FEV1% improvement after therapy.
4.QuantitativeCTinCOPD
4.1. Large and Intermediate Airway Assessment in COPD.
Small airways are the main site of obstruction in COPD
[1, 2]. However, large airways are not free of abnormalities.
Lee et al. deﬁned a tracheal index (TI) as the ratio between
the tracheal diameter measured on the coronal plane, and
the sagittal diameter. They showed signiﬁcant correlation
between TI and severity of emphysema [46]. Sverzelatti et
al. studied the prevalence of bronchial diverticula in smokers
[47]. Grade 2 was deﬁned as the presence of more than
three diverticulas in large airways. This feature correlated
with a more frequent history of cough, a greater extent of
emphysema, a more severe bronchial wall thickening, and a
heavier level of smoking.
Nakano et al. demonstrated that the mean dimensions
of large and intermediate airways with an internal perimeter
greater than 0.75cm predicted the mean dimensions of small
airways with an internal diameter of 1.25mm [48].
Several studies have shown that airway wall thickness
correlates with pulmonary function tests (PFTs) [49–53]. In
a study conducted in 114 smokers, Nakano et al. showed that
WA% measured on the trunk of the right apical bronchus
correlated with FEV1 predicted, forced vital capacity (FRC),
and residual volume/total lung capacity (RV/TLC) [49].
Grydeland et al. demonstrated that DLCO correlates with
both emphysema and airway wall thickness [50], though
Nakano et al. did not ﬁnd signiﬁcant correlation. Berger et
al. measured airway dimensions with spirometrically gated
CT. They showed that normalized WA and LA correlated
with FEV1 and FEF25%–75% in smokers with and without
COPD. Moreover, these dimensions were signiﬁcantly larger
in smokers with COPD than in smokers without COPD or
non smokers [51].
Achenbach et al. wondered whether the strong correla-
tions calculated between small airways dimensions and PFT
is overestimated by the point spread function (PSF) artefact,
or not. PSF involves blurring of the small airways contours
and can lead to overestimate them using the FWHM algo-
rithm. Using another three-dimensional approach taking
into account the PSF, they assessed a median of 619 orthogo-
nal airway locations per patient. They observed a signiﬁcant
correlation between airway dimensions and FEV1 in COPD
patients. This correlation was higher from large to small
airways, which is in agreement with FWHM principle [54].
Shimizu et al. have compared airway dimensions in 28
male COPD versus 12 sex and age-matched asthmatic and 13
age-matched healthy smokers. WA% and LA were measured
from the 3rd to the 6th generation. At any generation, WA%
was smaller and LA larger in COPD than in asthma,
followed by controls. FEV1 predicted and FEV1/FVC was
similar between asthma and COPD. They concluded that
remodelling is more prominent in asthma than in COPD
under stable clinical conditions [55].
Bronchial wall attenuation has been recently assessed in
COPD. Washko et al. and Yamashiro et al. used the FWHM
algorithm to extract the Peak Wall Attenuation value from
the bronchial wall, as a surrogate of its main density. They
showed strong correlations between this new biomarker
of airway wall structural changes and airway obstructions
assessed by PFT. Correlations were stronger in small airways.
However, PWA extracted with FWHM principle is not
independent from airway wall dimension [18, 19].
4.2. Lung Parenchyma Assessment in COPD. Ex vivo studies
inisolatedlungsandinvivoinvasivemeasurementsofairway
resistance revealed that distal airways are the main site of air-
ﬂow obstruction in COPD [5, 6]. Pathological studies high-
lighted that the small conductive airways are inﬁltrated by
phagocytes (macrophages and neutrophils), dendritic cells,
and T and B lymphocytes. Structural changes include airway
wall thickness and obstruction by muco-inﬂammatory exu-
datesandemphysema.Lungdensityprovidesanindirecttool
to assess them in vivo, though non speciﬁc.
Centrilobular nodules and branching lines are areas
of high attenuation and reﬂect pathological changes in
small conductive airways, either inﬂammation or ﬁbrosis.
Destruction of alveolar walls is the hallmark of emphysema,
and this pathological feature induces decreased areas of
lung attenuation. Using the density mask and the percentile
methods,Madanietal.showedthatthe −960HUvoxelindex
and the 1st percentile correlate with emphysema extent on
pathological examinations [56]. Gevenois et al. showed that
expiratory quantitative CT is not as accurate as inspiratory
CT to measure lung emphysema [57].
However, areas of decreasedattenuation canbe visible on
inspiratory images as a mosaic pattern, and air trapping on
expiratory images. Both obstruction of the small conductive
airways and loss of alveolar attachments are associated
with destabilisation and premature airway closure during
expiration. Therefore, diﬀerentiating emphysema from air
trapping is not reliably achievable on CT images when
assessed visually. Nevertheless, Matsuoka et al. have devel-
oped a quantitative method to evaluate it. They suggested
that voxels <950HU represent emphysema, and the relative
volume changes, between inspiration and expiration, of
voxels between −950HU and −860HU is thought to reﬂect
air trapping [58–61].
Another paradoxical fall in lung density has been re-
ported by Shaker et al. in COPD smokers. LAA% with a
voxel index of −910HU displayed a rapid fall in lung density
after smoking cessation, mimicking rapid progression of
emphysema. This was ascribed to an anti-inﬂammatory ef-
fect of smoking cessation and is not to be misinterpreted
[62]. Persistent airway inﬂammation and emphysema pro-
gression have been showed in exsmokers after 4-year smok-
ing cessation [63].
Correlations between the extent of emphysema and
pulmonary function tests have been long reported [64–69].
COPD is characterized by expiratory airﬂow limitation that
results in delayed emptying of the lung, poorly reversible.
LAA% has been shown to correlate with FVC% predicted,
FEV1% predicted, FEV1/FVC, RV/TLC, and DLCO/VA.Journal of Allergy 7
Gurney et al. studied emphysema distribution and showed
that predominantly lower lobe zones of emphysema are more
likely to correlate with obstructive dysfunction and DLCO
[70].
CTquantiﬁcationhasbeenassessedasapredictoroflung
function decline in smokers with normal PFTs. Tsushima
et al. reported that abnormal CT ﬁndings were predictive
of airﬂow limitation and development of emphysema in
s m o k e r sw i t hn o r m a lF E V 1[ 71]. Yuan et al. demonstrated
that CT quantiﬁcation of overinﬂation is predictive of FEV1
declineinsmokerswithnormallungfunction[72].Usingthe
15th percentile, Hoesein et al. demonstrated that the extent
of emphysema quantiﬁed by CT correlates with the lung
function decline assessed by FEV1 at 3-year followup [73].
CT has been used to explore clinical outcomes associated
with COPD. Mair et al. [74], and Ogawa et al. [75]r e p o r t e d
a negative correlation between LAA% and body mass
index (BMI), and emphysema dominant COPD phenotype
showed stronger negative correlation with BMI than airway
dominant. Ohara et al. reported that LAA% correlates with
signiﬁcant reduced bone density, as a biomarker of osteo-
porosis in COPD patients [76]. Independent associations
with thoracic calciﬁcation have been reported by Dransﬁeld
et al., suggesting that LAA% can be used as a risk factor of
cardiovascular disease in patients with and without COPD
[77]. Emphysema is associated with an increased risk of
lung cancer [78, 79]. Gull´ on et al. showed that presence of
emphysema in patients with nonsmall cells lung cancer aﬀect
the survival rate and can be consider a prognostic factor
[80]. Haruna et al. have followed up 251 COPD patients.
Among them, 79 died, and 40 deaths were attributable to
respiratory disease not involving lung cancer. A multivariate
analysis comparing age, PFT, BMI, and emphysema assessed
byCTrevealedthatLAA%hadthestrongestassociationwith
mortality [81].
Using CT quantiﬁcation, Shaker et al. did not ﬁnd signif-
icant correlation between CT emphysema quantiﬁcation and
emphysema progression after corticosteroid therapy [82].
Nevertheless, lung attenuation has been reported to be a
predictor of outcome after lung volume reduction surgery
in severe COPD. Wahsko et al. showed weak but statistically
signiﬁcant correlation between emphysema CT measures
and 6-month postoperative outcomes assessed by FEV1 and
maximal exercise changes [83]. Sciurba et al. demonstrated a
poorer survival postoperative rate in patients with increased
LAA%. Both studies did not show any signiﬁcant correlation
with airway wall thickness [84].
4.3. COPD Classiﬁcation Using CT. According to the Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
guideline, COPD is a disease state characterized by airﬂow
limitation that is not fully reversible. Irreversible airﬂow
limitation is deﬁned as FEV1/FVC < 70% after inhalation
of β2-agonist. Chronic bronchitis and emphysema are not
included in the GOLD deﬁnition, because they do not
allow accurate discrimination based on clinical symptomatic
features [85].
Nakano et al. suggested that CT is useful to discriminate
between patients who have primarily parenchyma disease
from those who have primarily airway pathology. Using
WA% and LAA% as objective and quantitative surrogates
of, respectively, airway and lung disease, they found that
they could divide COPD patients into groups; airway re-
modelling-dominant group (high WA% and low LAA%),
emphysema dominant group (low WA% and high LAA%),
and a mixed group (high WA% and high LAA%). They did
not study the clinical features associated with this classiﬁca-
tion based on morphological CT changes [86].
Fujimoto et al. classiﬁed COPD patients into three mor-
phological groups and studied their clinical and functional
signiﬁcation. The A phenotype was deﬁned as absence of
emphysema with or without bronchial wall thickening, E
phenotype as emphysema without wall thickening, and M
phenotype as a combination of emphysema and bronchial
wall thickening. They showed that the clinical features
between these three phenotypes were diﬀerent. The A phe-
notype showed a higher prevalence of nonsmoker COPD
patients, higher BMI and DLCO, and milder hyperinﬂation
compared with the E. The M phenotype showed a higher
prevalence of severe COPD, assessed by sputum level, pro-
ductive cough, wheezing, exacerbation, and hospitalizations.
A and M phenotypes showed greater airﬂow reversibility
of airﬂow limitation responsive to β2-agonist inhalation
compared with E [87, 88].
Fujimoto et al. studied the eﬃcacy of long-acting mus-
carinic antagonist (tiotropium) in COPD patients, classiﬁed
in dominant emphysema or nondominant on their morpho-
logical CT scans. Tiotropium improved airﬂow limitation
in all types, regardless to the emphysema dominance, and
dynamic hyperinﬂation in the emphysema dominant pheno-
type [89].
5.Perspectives
Strong eﬀorts have been made the last decade to assess CT
as a research tool to understand the role of resident cells
in asthma and COPD. This literature data screening show
that clinical and animal study is now available in vivo thanks
to MDCT technology. However, a cellular level of detection
has not been reached yet. Further developments need to be
performed to obtain cellular-speciﬁc quantiﬁcations.
Spatial resolution should be improved. Small conductive
airways inferior to 1mm are not clearly visible on CT
images, and they still need to be addressed. An indirect CT
parameter is provided by lung attenuation. Lung attenuation
is though nonspeciﬁc and may be altered by any change
in intralobular structures. Blurring eﬀect may also modify
CT wall thickness quantiﬁcation of small to intermediate
airways. A better delineation of these structures may allow
a better understanding of their alterations in asthma and
COPD.
Wall density is a new biomarker in asthma and COPD
which need further development. Only nonenhanced wall
attenuation has been reported. No data exists about CT-
enhancedwallattenuationvaluechanges.Forinstance,ﬁbro-
sis is typically characterized in organs by a delayed enhance-
mentonCTscansusinganiodinecontrastmedium,anddata
around peribronchial ﬁbrosis in COPD or chronic asthma8 Journal of Allergy
have not been reported. Speciﬁc contrast medium should be
developedtoenhancetargetcells,anddensitymaybetheone
tool to quantify possible enhancement.
Postprocessing softwares are to be improved. Just a few
n u m b e r so fb r o n c h i a lg e n e r a t i o n sa r ea v a i l a b l ef o r3 Ds e g -
mentation. The gradient of density between bronchial and
parenchyma air attenuation is not suitable for an accurate
segmentation beyond a few number of bronchi genera-
tions.
MRI techniques using noble hyperpolarized gases have
been reported, but they are cost eﬀective and not suitable
for a routine clinical or research practice widely used [90–
92]. To our knowledge, no data exists about proton MRI of
bronchi wall quantiﬁcation. Enhanced MRI using gadolin-
ium medium or others in bronchi wall is not documented.
Due to its inocuity, MRI should provide cine images of
bronchi diameter modiﬁcations under physiologic or patho-
logic conditions.
6. Conclusion
CT is an accurate tool to investigate in vivo asthma and
COPD physiopathology. Quantiﬁcation of airway wall and
lung parenchyma has demonstrated strong correlations with
clinical, functional, and pathological features, in humans or
in animal models. However, spatial resolution and speciﬁc
contrast medium need to be further developed to allow a
cellular level of detection which has not been reached yet.
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